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Abstract  
Aims: After myocardial infarction (MI), extensive remodeling of extracellular matrix  
contributes to scar formation. While aiming to preserve tissue integrity, this fibrotic response  
is also associated with adverse events, including a markedly increased risk of heart failure,  
ventricular arrhythmias and sudden cardiac death. Cardiac fibrosis is characterized by  
extensive deposition of collagen, but also by increased stiffness as a consequence of enhanced  
collagen cross-linking. Members of the lysyl oxidase (LOX) family of enzymes are  
responsible for the formation of collagen cross-links. The present study investigates the  
contribution of LOX family members to the heart response to myocardial infarction.  
Methods and Results: Experimental MI was induced in C57BL/6 mice by permanent  
ligation of the left anterior descending coronary artery. The expression of LOX isoforms  
(LOX and LOXL1 to 4) was strongly increased upon MI, and this response was accompanied  
by a significant accumulation of mature collagen fibers in the infarcted area. LOX expression  
was observed in areas of extensive remodeling, partially overlapping with -smooth muscle  
actin (-SMA)-expressing myofibroblasts. TGF-- as well as hypoxia-activated pathways  
contributed to the induction of LOX expression in cardiac fibroblasts. Finally, in vivo post- 
infarction treatment with the broad band LOX inhibitor -aminopropionitrile (BAPN) or,  
selectively, with a neutralizing antibody against the canonical LOX isoform attenuated  
collagen accumulation and maturation, and also resulted in reduced ventricular dilatation and  
improved cardiac function.  
Conclusions: LOX family members contribute significantly to the detrimental effects of  
cardiac remodeling, highlighting LOX inhibition as a potential therapeutic strategy for post- 
infarction recovery.  
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Non-standard Abbreviations and Acronyms 
ALK5: activin-like kinase 5. 
-SMA: -smooth muscle actin. 
BAPN: -aminopropionitrile. 
cTNI: cardiac troponin I. 
DAPI: 4',6-diamidino-2-phenylindole. 
ECM: extracellular matrix. 
HIF1: hypoxia-induced factor-1. 
HP: hydroxylysylpyridinoline. 
HPLC: high performance liquid chromatography. 
LOX: lysyl oxidase. 
LOXL: lysyl oxidase-like. 
LP: lysylpyridinoline. 
LV: left ventricule. 
LVESD: left ventricular end-systolic diameter. 
LVEDD: left ventricular end-diastolic diameter. 
MI: myocardial infarction. 
RT-PCR: reverse-transcribed polymerase chain reaction. 
SHR: spontaneous hypertensive rat. 
TGF-: transforming growth factor-. 
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Introduction  
Extensive remodeling of the cardiac extracellular matrix (ECM) occurs during myocardial  
infarction. As an orchestrated response to heart damage, loss of myocardial mass due to  
ischemia induces cardiac fibrosis, mainly, but not only, mediated by the transdifferentiation of  
fibroblasts to myofibroblasts, with significant collagen production and deposition1. Since  
adult mammals have a limited capacity to regenerate the cardiomyocytes after cell death, this  
“reparative” fibrotic response constitutes the only way for the entire organ to preserve its  
structural integrity, avoid rupture and maintain its pumping capacity. However, this  
progressively leads to cardiac remodeling, increased tissue stiffness and propensity to  
arrhythmias and eventually to heart failure.  
Collagen is a relatively stiff material with a high tensile strength; therefore tissue stiffness is  
expected to increase upon collagen deposition following a MI. However, recent studies have  
shown that increased collagen production and deposition in itself is not always directly  
translated into increased stiffness, and that myocardial damage results not only in an increase  
in collagen content but also in structural qualitative changes in collagen network2, 3. One of  
the characteristic features of collagen is its extensive post-translational modifications,  
including proline and lysine hydroxylation, glycosylation of specific hydroxylysine residues,  
oxidative deamination of the -amino groups of peptidyl lysine/hydroxylysine in the  
telopeptide domains of the molecule, and subsequent intra/intermolecular covalent cross- 
linking 4. Collagen tensile strength importantly relies on cross-linking 5. This has led to the  
proposal that it is not only the amount of collagen that matters; it is the cross-linking which  
determines the stiffness. In fact, enhanced collagen cross-linking has been observed in the  
failing human heart, and it has been further demonstrated that it is the degree of cross-linking  
that significantly correlates with chamber stiffness6, 7. The members of the lysyl oxidase  
(LOX) family are responsible for initiating covalent cross-linking formation by catalyzing the  
oxidative deamination of lysine/hydroxylysine residues in collagen telopeptide domains, a  
process progressing into non-enzymatically condensation of aldehyde groups to form the  
mature cross-links. Five different LOX enzymes have been identified in mammals, the  
canonical LOX, and four LOX-like isoforms, LOXL1-48. Abnormally increased expression of  
the active form of LOX and of LOX mRNA has been reported in the fibrotic myocardium of  
patients with heart disease9. LOX mRNA and protein have been also found to be upregulated  
in animal models of heart failure, including MI, together with a significant increase in  
collagen cross-linking and chamber stiffness10, 11.   
Based on these clinical and experimental observations, it is conceivable that LOX  
upregulation may play a significant role in cardiac remodeling upon MI. Nevertheless, the  
specific contribution of the LOX family members in the response to MI and whether they play  
beneficial or detrimental roles during heart remodeling is virtually unknown. In this work, we  
aimed to assess the expression of LOX isoforms in a mouse model of MI, as well as to  
analyze the main cell type/s responsible for their expression. Finally, we studied the  
contribution of this family of enzymes to cardiac remodeling and function, as an obligate step  
in their validation as pharmacological target for post-MI treatment.  
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Methods  
A detailed description of the methods is provided in Supplementary material online.  
  
Mouse model of myocardial infarction  
MI was induced in C57BL/6 by permanently ligating the left coronary artery as previously  
described12. Control, uninfarcted animals were sham-operated.  
Cardiac function, chamber dilatation, and wall thickness were analyzed by transthoracic  
echocardiography 3 and 28 days after infarction, as well as in uninfarcted mice, using a Vevo  
2100 high resolution ultrasound system equipped with a 30-MHz linear array transducer   
(Visualsonics, Toronto, Canada). For LOX inhibition studies, mice were treated either with - 
aminopropionitrile (BAPN, 5 mg/kg body weight/day; Sigma-Aldrich, St. Louis, Missouri)  
(n=10 per group) or with a rabbit polyclonal antibody reported to specifically block LOX  
isoform (1 mg/kg body weight/twice weekly), injected intraperitoneally (n=5 per group) 13.  
Control mice received PBS as vehicle for BAPN, or the same amount of control IgG (Sigma- 
Aldrich) for anti-LOX. In two experimental groups, BAPN treatment started either on the  
same day or eight days after MI. The administration of anti-LOX antibody was initiated eight  
days after MI. Both animal trials were ended at day 28 post-infarction. Animals were  
sacrificed by gradually filling the chamber with carbon dioxide.  
The investigation conforms to the principles of Laboratory Animal Care, which are  
formulated by the National Society for Medical Research and the Guide for the Care and Use  
of Laboratory Animals (US National Institutes of Health, 2011), and the Directive  
2010/63/EU of the European Parliament on the protection of animals used for scientific  
purposes.  
  
Histological and immunohistochemical studies  
The extent of cardiac damage and fibrosis was assessed by standard histological and  
immunohistochemical methodologies. Immunohistochemical stainings and double  
immunofluorescence were performed using methods previously described 14.   
  
RNA extraction and quantitative real-time reverse-transcribed polymerase chain  
reaction  
For RNA studies, heart tissue was snap-frozen in liquid nitrogen. Total RNA was extracted  
using the RNAeasy kit (Qiagen), the cDNA was synthesized (iScript cDNA synthesis kit,  
Bio-Rad, Hercules, California) and quantitative real time reverse-transcribed polymerase  
chain reaction (RT-PCR) was performed as described with off-the-shelf Taqman probes  
(Applied Biosystems, Foster City, California) 12.   
  
Collagen and collagen cross-linking analysis  
Heart tissue portions were hydrolyzed (110°C, 24 hours) in 6 M HCl and collagen  
(hydroxyproline and proline) and mature trivalent cross-links, hydroxylysylpyridinoline (HP)  
and lysylpyridinoline (LP), analyzed as described previously 15.   
  
Culture of cardiac fibroblasts  
Mice were sacrificed by gradually filling the chamber with carbon dioxide and cardiac  
fibroblasts were isolated from 8-week old mouse heart tissue using methods previously  
described 16. Mouse cardiac fibroblasts were treated for time periods ranging from 8 to 48  
hours with TGF-1 at 5 ng/ml under normoxic or hypoxic conditions (1% O2 tension,  
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Hypoxystation H35, Don Whitley, Shipley, England). At the end of the experimental period,  
total RNA or protein were extracted and analyzed following protocols previously described14.  
  
Statistical Analysis  
Data are presented as mean ± SE. In echocardiographic data, the same mice were analyzed 3  
and 28 days post-infarction, with non-infarcted animals representing a different group of  
mice. To test for statistical significance, data were analyzed by one- or two-way ANOVA  
followed by Bonferroni post-test, or by unpaired t-test as indicated in the corresponding table  
and figure legends. Statistics was performed with GraphPad Prism 5.0 (La Jolla, California),  
and differences were considered statistically significant at P< 0.05.  
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Results  
Increased LOX and LOXL expression after MI  
In order to gain insight about the potential contribution of LOX family members to the heart  
response to MI, we established an infarct mouse model with permanent ligation of the left  
anterior descending artery. Cross-sections of the ventricles stained with Picrosirius red and  
visualized under brightfield light microscopy showed that coronary artery ligation resulted in  
large transmural infarcts with progressive accumulation of collagen and left ventricular wall  
thinning in the infarct area (Supp. Fig. 1A-C). Interestingly, collagen visualization by  
Picrosirius red staining under polarized light showed long and highly aligned collagen fibers  
in the remodeled heart of mice at 7-28 days post injury, in marked contrast to mice with no  
infarct or those sacrificed 3 days after coronary ligation, which displayed an almost black  
background (Fig. 1A). Quantification of immature (greenish-yellow) and mature (reddish- 
orange) collagen revealed a progressive accumulation of mature fibers when compared to  
immature collagen (Fig. 1B). While the presence of highly birefringent collagen scaffolds  
does not directly demonstrate enhanced cross-linking, these observations indicate the  
potential involvement of LOX upregulation in the formation of mature collagen bundles in the  
fibrotic scar of the infarcted heart. In order to analyze the expression profile of LOX family  
members in response to MI, three heart regions were defined corresponding to the scar  
(infarct), the peri-infarct (border), and the sites distant from the infarct area (remote), as  
indicated in the micrograph taken 28 days post injury (Supp. Fig. 1A). Total RNA was  
extracted from these regions and analyzed by real time quantitative RT-PCR. Compared with  
uninjured hearts, MI induced increases in the expression of the whole set of LOX genes in all  
areas studied, with higher induction rates in the infarct, diminishing gradually in border and  
remote zones (Fig. 1C). Gene expression increases were detectable at 3 days post injury and  
peaked between 3-7 days for all of the isoforms. These results were confirmed by  
immunohistochemical analysis for LOX, LOXL2 and LOXL4 at 7 days after coronary  
ligation as compared with control (Fig. 2A, 2B). Available antibodies for LOXL1 and  
LOXL3 did not work in our hands (data not shown).   
Myofibroblasts dominate the regulation of collagen turnover in the injured heart1. In order to  
study whether myofibroblasts are the main source for the expression of LOX after myocardial  
infarction, consecutive cross-sections of control and infarcted hearts (7 days post-MI) were  
analyzed for the expression of the canonical LOX, the most highly induced LOX isoform in  
our experimental conditions, and of the myofibroblast marker -smooth muscle actin (- 
SMA). As shown in Fig. 3A, LOX expression was found to be associated with areas of  
extensive tissue remodeling with the presence of positively birefringent collagen fibers,  
partially overlapping with extravascular -SMA-positive cells. Staining with the  
cardiomyocyte-specific marker cardiac troponin I (cTNI) showed a faint labeling of LOX in  
cTNI-rich regions around the injured heart, whereas CD45-positive leukocytes seems not to  
display specific LOX staining (Supp. Fig. 2). The expression of LOX by extravascular - 
SMA-positive myofibroblasts was also studied by immunofluorescence. As shown in Fig. 3B,  
positive co-localization of LOX and -SMA was observed in the injured heart, but we also  
found a number of LOX-expressing cells that were negative (or very low stained) for -SMA.  
Taken together, these results show that LOX family members are highly induced in response  
to myocardial infarction, presumably contributing to cardiac remodeling by collagen cross- 
linking, and that myofibroblasts constitute a cell source for the expression of LOX.  
  
TGF- and hypoxia induce LOX and LOXL expression in cardiac fibroblasts  
Next, we investigated whether the induction of LOX genes can be recapitulated in cardiac  
fibroblasts and analyzed the signal transduction pathways potentially involved. Previous work  
from different groups including ours has shown that TGF- and hypoxia are important stimuli  
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for LOX/L expression in a number of cells and tissues17-20. Clinical and experimental  
evidence point also to a role for TGF-- and hypoxia-dependent pathways in the heart  
response to myocardial infarction21-24. Accordingly, we found that TGF-- and hypoxia- 
dependent pathways were activated in our model of MI as assessed by phospho-Smad and  
HIF1 staining, respectively (Fig. 4A and B). We then isolated cardiac fibroblasts from  
mouse ventricles, exposed them under culture conditions to 5 ng/ml of TGF-1 and hypoxia  
(1% O2 tension) or both, and analyzed the expression of LOX/L isoforms. Under our  
experimental conditions, only TGF- stimulus was able to promote myofibroblast  
differentiation, as assessed by -SMA expression (Supp. Fig. 3). As shown in Fig. 4C, TGF- 
 and hypoxia induced the expression of the whole set of LOX isoforms, except for LOXL1  
by TGF-1, as assessed by quantitative RT-PCR. The combination of both stimuli was  
particularly effective to upregulate the expression of LOX and LOXL2. The induction of the  
canonical LOX mRNA is followed by protein expression and accumulation in the cell  
supernatant, as shown in Fig. 4D and E. Taken together, these results indicate that the  
induction of LOX isoforms can be recapitulated in vitro by activation of TGF-- and hypoxia- 
dependent pathways in cardiac fibroblasts.  
  
LOX activity inhibition improves cardiac function after MI  
We show here that LOX/L enzymes are induced as a response to MI at 3-7 days after injury.  
To determine the role of LOX in heart remodeling following MI, we studied the effect of the  
inhibition of LOX activity with the small molecule -aminopropionitrile (BAPN) in the MI  
mouse model. BAPN (5 mg/kg body weight/day) was administered daily to control animals  
(sham-operated) and to infarcted mice, starting 8 days after surgery. The extent of collagen  
content and cross-linking was studied in the scar area by biochemical and histological  
techniques in the control and BAPN-receiving animals. HPLC-based biochemical evaluation  
showed a modest though significant increase in the amount of the major stable mature cross- 
link 28 days post-MI, as represented by hydroxylysylpyridinoline (HP)/triple helix, together  
with an increase in collagen accumulation, expressed as hydroxyproline/proline ratio (Fig. 5A  
and B). LOX inhibition with BAPN resulted in a significant reduction in both collagen cross- 
linking and content. Interestingly, careful analysis under polarized light of the accumulated  
collagen revealed a diminished presence of orange-red mature collagen bundles in control  
mice compared to the green-yellow fibers observed in BAPN-treated (Fig. 5C and D). Heart  
tissue sections stained with Picrosirius red showed a significant reduction in the extent of the  
fibrotic scar area in BAPN-treated mice 28 days post-MI, as well as a diminished infarct  
length (Fig. 5E and F). In agreement with these results, BAPN treatment resulted in a  
reduction in the number of ventricular wall segments with reduced motility as measured by  
echocardiography, suggesting that BAPN-treated animals have reduced infarct expansion  
compared to control animals (Table 1). We next analyzed whether BAPN treatment altered  
the expression of LOX isoforms and certain metalloproteases (MMP) reported to be involved  
in the heart response to damage 25. As shown in Supp. Fig. 4, except LOXL1 and MMP9, the  
expression of these matrix remodeling enzymes was found to be upregulated at 28 days post- 
infarction, and did not change upon BAPN treatment. Interestingly, the expression of the  
metalloprotease inhibitor TIMP4 was diminished upon MI, and this downregulation was not  
observed in infarcted mice under BAPN administration.  
To assess cardiac function we carried out echocardiographic analysis 3 and 28 days post- 
injury as well as in uninjured mice. BAPN did not significantly alter cardiac function in  
control animals (Table 2). However, BAPN administration, starting either 8 days after MI or  
on the same day of the intervention, reduced ventricular dilatation and improved ejection  
fraction 28 days post injury, compared to untreated animals. Improved function was  
accompanied by a reduction in the heart weight/body weight ratio (Supp. Table. 1).  
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Only a few number of molecules have been identified as potential LOX inhibitors (being  
BAPN the most widely used compound), and even fewer as selectively blocking one  
particular isoform 26, 27. To confirm the role of LOX in post-MI cardiac remodeling, we  
carried out additional experiments using a rabbit polyclonal antibody that blocks canonical  
LOX activity in vivo 28. As shown in Fig. 6, mice subjected to MI and receiving anti-LOX  
antibody displayed reduced cardiac fibrosis and diminished scar area and infarct size,  
compared with mice treated with rabbit IgG as a control. Mice treated with anti-LOX  
antibody displayed significantly reduced ventricular dilatation and improved ejection fraction  
28 days post-infarction. This was paralleled by a reduction in the number of ventricular wall  
segments with reduced motility as measured by echocardiography (Tables 3 and 4).  
Taken together our results indicate that the inhibition of LOX enzymatic activity, particularly  
that of the canonical LOX, impairs the formation of a mature collagen matrix upon  
myocardial infarction, and that this is associated with a beneficial effect on cardiac  
remodeling and function.  
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Discussion  
The family of LOX enzymes has attracted considerable interest in recent years as their  
members have been associated with several diseases, particularly in the vascular system and  
in tumorigenesis29, 30. Although biological roles beyond ECM remodeling have been  
described for LOX members, such as chromatin regulation or cellular chemotaxis, most  
reported actions in the vascular and cancer settings invoke the capacity of these enzymes to  
contribute to ECM building and maintenance29, 31. In the cardiovascular system, where the  
ECM plays an essential role in providing the biomechanical properties, pioneering work by  
Lerman et al. reported that LOX activity increased during the healing response to acute  
myocardial infarction in rabbits 32. Augmented expression of the canonical LOX has been also  
reported during the myocardial fibrotic response occurring in spontaneously hypertensive rats  
(SHR), an observation linked to enhanced collagen cross-linking and deposition9. Additional  
experimental models, such as C57/BL6 mice under a high fat and carbohydrate diet, a model  
of metabolic syndrome, or rhesus monkeys subjected to left anterior descending artery  
ligation, developed myocardial fibrosis with increases in collagen cross-linking and LOX  
activity and/or expression 33, 34. Clinically, myocardial fibrosis in patients with hypertensive  
heart disease and chronic heart failure is associated with enhanced LOX expression and  
matrix cross-linking9. These studies investigating the role of LOX in heart diseases were  
mainly focused on the analysis of the expression of the canonical LOX, with no or very little  
information on the remaining isoforms. Here we show, to our knowledge for the first time,  
that the whole set of LOX genes were strongly upregulated in an infarct mouse model.  
Coordinated expression of all the LOX family members suggests that common signaling  
pathways are triggered to induce their expression during heart response to injury. TGF- and  
hypoxia have been previously shown to be important regulators of the expression of multiple  
LOX family members in other cell and tissue contexts18, 20. Here we also show that, in  
agreement with previous studies, these signaling pathways were indeed activated after  
myocardial infarction and promoted the expression of LOX/L in cultured cardiac fibroblasts,  
the main cell type giving rise to myofibroblasts in the fibrotic heart21-24. To this respect,  
although TGF- has been described to have a preeminent role in gene expression changes  
occurring during cardiac fibrosis, tissue hypoxia is a common feature of different conditions  
leading to cardiac fibrosis, including myocardial infarction and pressure- or volume-overload,  
and has been reported to induce ECM accumulation and myofibroblast differentiation in  
cardiac fibroblasts35-37. The acquisition of a contractile phenotype by expression of -SMA is  
widely used to identify differentiated myofibroblasts 38. Here we describe that extravascular  
-SMA-positive cells constitute a cell source for the expression of the canonical LOX  
isoform, the most highly upregulated isoform upon myocardial damage39. It should be  
however noted that some cells negative or low stained for -SMA were also found to  
contribute to LOX expression. While the nature of these cells is at present unknown, different  
authors have reported a significant developmental heterogeneity in the origin of cardiac  
fibroblasts, with the presence of fibroblast cell lineages not expressing -SMA 40-42. To make  
this issue even more complicated, cardiomyocytes have been reported to express LOXL1  
upon stimulation with hypertrophic agonists, and T-lymphocytes have been described to  
regulate cardiac fibroblast LOX expression 43, 44. In fact, our study also detected upregulation  
of expression of LOX in cardiomyocytes in the infarcted region; nevertheless this expression  
was considerably lower than that observed in myofibroblasts.   
Deposition and cross-linking of fibrillar collagen during the heart response to damage confers  
strength that opposes to scar and chamber deformation, but has also a tremendous impact on  
the mechanical and electrical properties of the myocardium. Antifibrotic and cardioprotective  
strategies have extensively focused on the attenuation of the fibrotic response 45, 46. Given that  
the activation of the TGF- signaling plays an important role in the initiation and progression  
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of the fibrotic process, a number of strategies have been established to block or mitigate this  
signaling pathway in order to reduce cardiac remodeling, unfortunately, without a clear  
answer. While some studies have reported detrimental effects of TGF- inhibition in a MI  
experimental model, other works described that TGF- signaling blockade by ALK5  
inhibition successfully ameliorated myocardial collagen accumulation and cardiac  
dysfunction 47, 48. More recently, a small molecule inhibiting ALK5 has been reported to  
improve cardiac function, and to diminish collagen and collagen cross-linking accumulation  
49. This is in agreement with reports describing the capacity of TGF- inhibitory peptides to  
improve cardiac function, in association with reduced collagen cross-linking and LOX  
expression, in experimental models of pressure overload, though this reflects a distinct  
clinical condition, presumably being governed by different pathogenetic mechanisms9.  
Whereas there is still some controversy, these findings support TGF- signaling blockade as  
an effective therapy to prevent cardiac dysfunction. Nevertheless, their translation to the  
clinical setting is challenging due to the pleiotropic nature of TGF- and its modulatory  
functions of the immune and inflammatory responses. Specific intervention of TGF-  
downstream targets contributing to tissue fibrosis might represent more realistic options for  
the clinical treatment, such as the inhibition of LOX-mediated matrix crosslinking. Using  
BAPN, it was previously shown that inhibition of LOX enzymatic activity decreased chamber  
and myocardial stiffness in pigs, therefore proving that these enzymes are important  
determinants of the biomechanical properties of the intact heart 50. Upon heart damage,  
inhibition of LOX activity impaired the accumulation of collagen in a model of cardiac  
hypertrophy in rats, and more recently, BAPN reduced myocardial fibrosis in a mouse model  
of aging 51, 52. While these experiments anticipated the potential use of LOX inhibitors for the  
treatment of heart disease, the specific contribution of LOX enzymes to cardiac dysfunction in  
disease models had not been clarified. Here we show that BAPN administration, starting  
either on the day of the coronary occlusion or 8 days after, reduced the accumulation of  
mature collagen after chronic MI and this effect was accompanied by reduced ventricular  
remodeling and improved cardiac function. Although ECM production and maturation is  
necessary to prevent cardiac rupture after MI, excessive matrix stiffness is associated with  
increased ventricular dilatation and reduced cardiac function in chronic MI. Based on our  
observations, LOX enzymes seem to play an important role in the tissue response to damage,  
and, therefore, LOX inhibitors could be of potential clinical application to treat post-infarction  
remodeling. Nevertheless, the clinical applicability of LOX inhibition in fibrotic and  
tumorigenic settings has been seriously questioned due to potential side effects and the lack of  
selective/specific inhibitors 27. In this line, BAPN is also referred to be the main factor  
responsible for osteolathyrism, defined as bone and tissue weakening associated to dietary  
consumption of seeds of Lathyrus sativus or grass pea, this action relying on its capacity to  
inhibit LOX activity 53. To this respect, we did not observe in BAPN-treated mice any  
particular case of cardiac rupture, nor the formation of aortic aneurysms, one of the clinical  
manifestations described to be associated to LOX inhibition 54. In fact, human pilot studies  
using BAPN in specific fibrosis-like pathologies, such as the complications associated to  
filtration surgery in glaucoma patients 55, have been carried out without serious side effects,  
and therefore, clinical suitability might be reached if safe dosage and time for treatment  
parameters are determined. Although decades of research have provided sufficient knowledge  
to confirm the fundamental role of LOX family members in several pathophysiological  
scenarios, only a few number of molecules have been characterized as potential LOX  
inhibitors (being BAPN the most widely used), and even fewer as selectively blocking one  
particular isoform 26, 27. Here we show that specific inhibition of the canonical LOX isoform  
by using a blocking antibody reduced cardiac fibrosis and infarct expansion, leading to a  
significant improvement in cardiac remodeling and function and suggesting a preeminent role  
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of this isoform in post-MI remodeling. To this respect, the relevance of this enzyme in cardiac  
pathophysiology has been recently recognized as the matricellular protein, osteopontin, found  
to be upregulated during myocardial remodeling in heart failure patients, was reported to  
promote cardiac fibrosis through activation of the expression and activity of LOX 56.  
In conclusion, our results show that LOX family members are highly induced during the  
response to myocardial infarction and play a significant role in the development of cardiac  
fibrosis, presumably by activation of TGF-- and hypoxia-dependent pathways in cardiac  
fibroblasts. We also show that the interference with the enzymatic activity of LOX proteins,  
particularly of the canonical LOX isoform, reduces ventricular remodeling and improves  
cardiac function in a mouse model of MI, and therefore we believe that this family of  
enzymes may represent a potential therapeutic target in cardiac fibrosis and post-ischemic  
heart failure. Nevertheless, more research, including the design and development of better  
inhibitors as well as additional in vivo analysis of potential side effects, is demanded in order  
to consider this family of proteins as a target for clinical intervention.  
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FIGURE LEGENDS  
  
Figure 1. Lysyl oxidase isoforms are induced after myocardial infarction in mice. Time  
course of collagen accumulation in mice subjected to myocardial infarction as visualized by  
Picrosirius red staining under brightfield (upper panels) and polarized light (lower panels).  
(A) Representative micrographs and (B) analysis of the percentage of heart area occupied by  
immature (greenish-yellow) and mature (reddish-orange) collagen (left panel) and the fraction  
of mature collagen (right panel) shown as a function of time (A, B, n=5). (C) LOX and LOXL  
expression was analyzed by quantitative RT-PCR in infarct, border and remote areas (mean ±  
standard error; n=5, one-way ANOVA followed by Bonferroni’s post test, *P<0.05 versus no  
infarction, **P<0.01 versus no infarction, dpi: days post-infarction).  
  
Figure 2. Immunohistochemistry of LOX, LOXL2 and LOXL4. Representative  
micrographs (A) and analysis of the percentage of area showing positive immunostaining (B)  
in the infarct scar 7 days after MI (mean ± standard error; unpaired t-test, n=5, *P<0.05 versus  
no infarction, **P<0.01 versus no infarction).  
  
Figure 3. Identification of cells expressing LOX in the infarct scar. A) Representative  
micrographs of consecutive heart tissue sections from control and MI mice (7 days post- 
infarction) analyzed by immunohistochemistry for the expression of LOX and the  
myofibroblast marker, -smooth muscle actin (-SMA), together with histological staining  
for collagen accumulation by Picrosirius red (PSR) under brightfield and polarized light.  
Arrows indicate areas where LOX and extravascular -SMA expression associates with the  
presence of positively birefringent collagen fibers. B) Representative micrographs of double  
immunofluorescence of heart sections from control and MI mice (7 days post-infarction)  
stained for LOX and -SMA (nuclei with DAPI), and merged images. Under control  
conditions LOX expression was below detection levels and -SMA only stained blood  
vessels. LOX expression was strongly increased upon MI and found to be associated to both  
-SMA-positive and negative (or low stained) cells (see arrows). A, B, n=5.  
  
Figure 4. TGF- and hypoxia induce LOX expression in cardiac fibroblasts.  
Immunohistochemical analysis of activation of TGF- and hypoxia-dependent pathways upon  
myocardial infarction (7 days after MI) in mice as visualized with specific phospho-Smad2  
(p-SMAD2) and HIF1 antibodies. (A) Representative micrographs from control and  
infarcted hearts (MI) and (B) analysis of percentage of area in the infarct region showing  
positive immunostaining (mean ± standard error; one-way ANOVA followed by Bonferroni’s  
post test, n=5, *P<0.05 versus no infarction, **P<0.01 versus no infarction). (C) Time course  
of induction of Lox/l mRNA expression by TGF- 5 ng/ml, hypoxia (1% O2) or both stimuli  
simultaneously in cultured cardiac fibroblasts in vitro as assessed by quantitative RT-PCR  
(mean ± standard error; one-way ANOVA followed by Bonferroni’s post test, n=6, *P<0.05  
versus unstimulated, **P<0.01 versus unstimulated). (D, E) Detection of LOX protein  
expression in hypoxia- and TGF--stimulated cardiac fibroblasts (48 hours of incubation). (D)  
Representative gels assayed for LOX and -actin (loading control) in total cell extracts (lower  
panels). Cell supernatants were saved, concentrated and assayed for LOX (upper panel). (E)  
Protein band intensities in cell supernatants (mean ± standard error; one-way ANOVA  
followed by Bonferroni’s post test, n=5, **P<0.01 versus unstimulated)  
  
Figure 5. LOX inhibition attenuates cardiac fibrosis. Collagen cross-linking (A) and  
content (B) in control and MI mice treated with vehicle or BAPN (starting 8 days after  
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coronary artery ligation) was measured in the scar area at 28 days post-infarction and  
expressed as hydroxylysylpyridinoline (HP)/triple helix and hydroxyproline/proline ratio,  
respectively (mean ± standard error; two-way ANOVA followed by Bonferroni’s post test,  
n=4, *P<0.05 versus control, **P<0.01 versus control). Collagen staining in heart tissue  
sections from MI mice under vehicle or BAPN at 28 days post-infarction was visualized by  
Picrosirius red staining under brightfield and polarized light. (C) Representative micrographs,  
and (D) analysis of the percentage of heart area occupied by immature (greenish-yellow) and  
mature (reddish-orange) collagen (C, D, n=5). (E) Representative whole tissue sections from  
infarcted mice treated with BAPN or vehicle and stained with Picrosirius red. (F) Analysis of  
scar area (percentage of the area occupied by scar) and infarct size (fraction of infarcted left  
ventricle circumference) (mean ± standard error; unpaired t-test, n=10, **P<0.01 versus  
vehicle).  
  
Figure 6. Selective LOX inhibition ameliorates cardiac fibrosis. Infarcted mice were  
treated with a neutralizing LOX antibody or control IgG (1 mg/kg body weight/twice weekly),  
injected intraperitoneally starting eight days after coronary occlusion. Collagen staining in  
heart tissue sections from mice at 28 days post-infarction was visualized by Picrosirius red  
staining under brightfield and polarized light. (A) Representative micrographs, and (B)  
analysis of the percentage of heart area occupied by immature (greenish-yellow) and mature  
(reddish-orange) collagen (A, B, n=4). (C) Representative whole tissue sections from  
infarcted mice treated with anti-LOX or control IgG and stained with Picrosirius red. (D)  
Analysis of scar area (percentage of the area occupied by scar) and infarct size (fraction of  
infarcted left ventricle circumference) (mean ± standard error; unpaired t-test, n=5, **P<0.01  
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Table 1. Administration of BAPN infarction reduces ventricular dilatation and improves 
cardiac function after myocardial. Myocardial infarction was induced by ligation of the left 
coronary artery in male mice and echocardiography analysis was carried out 3 and 28 days later. In 
the indicated group, BAPN was injected i.p. strating either 8 days post-infarction (d8) or on the day 
of the surgery (d0). Mean values ±SE are shown. Note that animals used for analysis with no MI are 
different from those who underwent surgeries. *p<0.05 infarcted vs no MI, †p<0.05 BAPN vs 
Control, 2-way ANOVA plus Bonferroni post-test. ‡p<0.05 28 days post-MI vs 3 days post-MI 
repeated-measures 2-way ANOVA plus Bonferroni post-test. #p<0.05 t-test BAPN vs Control. EF, 
ejection fraction;EF, EF at 28 days minus EF at 3 days; LVESV, left ventricular end systolic 
volume; LVEDV, left ventricular end diastolic volume; n, number of mice; pp, percentage points. 
 
 












Table 2. BAPN reduces infarct expansion and improves cardiac motility after myocardial 
infarction. Myocardial infarction was induced by ligation of the left coronary artery and 
echocardiography analysis was carried out 28 days later in the long axis. Where indicated, BAPN 
was administered to the mice starting either 0 (d0) or 8 days post-MI (d8). Left ventricular wall 
motility was evaluated by echocardiography in the parasternal long-axis view and scored as 
follows: 1, normal or hyperkinesis; 2, hypokinesis; 3, akinesis (negligible thickening); 4, dyskinesis 
(paradoxical systolic motion); 5, aneurysmal (diastolic deformation) 57. Mean values ±SE are shown 
for each of the six LV segments. n Dysfunctional segments represents the average number of 
segments with abnormal motility (infarcted). Total score represents the sum of the score of the six 
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Table 3. Administration of a neutralizing anti-LOX antibody improves cardiac function after 
myocardial infarction. Echocardiography analysis was carried out 3 and 28 days after inducing 
myocardial infarction by ligation of the left coronary artery. Anti-LOX antibody or IgG controls 
were injected i.p. 3 times a week starting 8 days post-infarction. Mean values ±SE are shown. Note 
that animals used for analysis with no MI are different from those who underwent surgeries. These 
uninjured animals were treated with antibodies for 21 days before analysis. *p<0.05 infarcted vs no 
MI, †p<0.05 anti-LOX vs IgG Control, 2-way ANOVA plus Bonferroni post-test. ‡p<0.05 28 days 
post-MI vs 3 days post-MI repeated-measures 2-way ANOVA plus Bonferroni post-test. EF, 
ejection fraction;EF, EF at 28 days minus EF at 3 days; LVESV, left ventricular end systolic 
volume; LVEDV, left ventricular end diastolic volume; n, number of mice; pp, percentage points. 
 












Table 4. LOX inhibition reduces infarct expansion and improves cardiac motility of the 
infarcted heart. Echocardiography analysis in the long axis was carried out 28 days after inducing 
myocardial infarction by ligation of the left coronary artery. A neutralizing anti-LOX antibody or 
control IgG were administered i.p. to the mice 3 times a week starting 8 days post-MI. Left 
ventricular wall motility was evaluated by echocardiography in the parasternal long-axis view and 
scored as follows: 1, normal or hyperkinesis; 2, hypokinesis; 3, akinesis (negligible thickening); 4, 
dyskinesis (paradoxical systolic motion); 5, aneurysmal (diastolic deformation) 57. Mean values 
±SE are shown for each of the six LV segments. n Dysfunctional segments represents the average 
number of segments with abnormal motility. Total score represents the sum of the score of the six 
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 2 
Methods 
Mice, surgeries and echocardiographic analysis 
Myocardial infarction was induced in ten-week-old male C57BL/6 mice (Charles River, 
Barcelona, Spain) (n=80) by permanently ligating the left coronary artery as previously 
described1. Surgeries were carried out under mechanical ventilation with 3–3.5% 
sevoflurane. Mice were administered analgesic treatment with buprenorphine (0.3 
mg/kg, s.c.) after surgery. The mortality rate in the first 24 h post-infarction was 38%; 
no mortality was found afterwards. Control, uninfarcted animals were sham-operated. 
Cardiac function, chamber dilatation, and wall thickness were analyzed by transthoracic 
echocardiography 3 and 28 days after infarction, as well as in uninfarcted mice, using a 
Vevo 2100 high resolution ultrasound system equipped with a 30-MHz linear array 
transducer  (Visualsonics, Toronto, Canada). Measurements were taken by a blinded 
operator with mice placed on a heating pad under light anaesthesia with isoflurane 
adjusted to obtain a target heart rate of 500 ± 50 bpm. Continual ECG monitoring was 
obtained via limb electrodes and synchronized with the ultrasound image. Two-
dimensional (2D) and M-mode echocardiography images were recorded in a long and 
short axis view and the M-mode sample gate was placed at the level of the papillary 
muscles. Image depth, width and gain were adjusted individually to optimize the image 
quality and to maintain a frame rate > 200 frames per second.  
Echocardiography studies were digitally stored and the analysis was performed off-line 
(Vevo 2100 Analytic Software). Left ventricular end-systolic volume (LVESV) and left 
ventricular end-diastolic volume (LVEDV) were measured from 2D parasternal long 
axis view using bi-plane area–length method and  LV ejection fraction (EF)  was 
automatically calculated by the formula ([LVEDV−LVESV]/LVEDV)×100%. The 
short-axis M-mode images were used to measure left ventricular end-diastolic and end-
systolic internal diameter (LVIDd and LVIDs, respectively), left ventricular end-
diastolic and end-systolic anterior wall thickness (LVAWd and LVAWs, respectively) 
and left ventricular diastolic and systolic posterior wall thickness (LVPWd and LVPWs, 
respectively. Mice presenting an EF above 45% at 3d post-MI were removed from the 
study.  Estimation of infarct size was performed by echocardiography in the 
paraesternal long axis view. For this purpose, the left ventricle was divided into six 
different segments (basal, mid and apical, in the anterior and posterior wall) and 
regional left ventricular function was evaluated in each segment as previous described 
by the American Society of Echocardiography by a blinded operator (1: normal or 
hyperkinetic; 2: hypokinetic; 3: akinetic; 4: dyskinetic, paradoxical systolic motion; 5: 
aneurysmal, diastolic deformation). The number of dysfunctional segments observed 
and the sum of the individual scores assigned to each of the six segments were 
employed to estimate the infarct size 2. 
For LOX inhibition studies, mice were treated either with -aminopropionitrile (BAPN, 
5 mg/kg body weight/day; Sigma-Aldrich, St. Louis, Missouri) (n=10 per group) or with 
a rabbit polyclonal antibody reported to specifically block LOX isoform (1 mg/kg body 
weight/twice weekly), injected intraperitoneally (n=5 per group) 3. Control mice 
received PBS as vehicle for BAPN, or the same amount of control IgG (Sigma-Aldrich) 
for anti-LOX. BAPN treatment started either on the same day or eight days after 
coronary occlusion. The administration of anti-LOX antibody was initiated eight days 
after. Both animal trials were ended at day 28 post-infarction. Animals were sacrificed 
by gradually filling the chamber with carbon dioxide. 
All experiments were approved by the local Ethics Committee at the Centro Nacional de 
Investigaciones Cardiovasculares (PA0410). The investigation conforms to the 
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principles of Laboratory Animal Care, which are formulated by the National Society for 
Medical Research and the Guide for the Care and Use of Laboratory Animals (US 
National Institutes of Health Publication 85-23, 1996), and the Directive 2010/63/EU of 
the European Parliament on the protection of animals used for scientific purposes. 
 
Histological and immunohistochemical studies 
The extent of cardiac damage and fibrosis was assessed by standard histological and 
immunohistochemical methodologies. Tissue portions were fixed in 4% 
paraformaldehyde and embedded in paraffin wax for histological and 
immunohistochemical studies. Cross-sectional 7-μm slices of paraffin-embedded heart 
tissue were deparaffinized, stained for collagen with Picrosirius red, and counterstained 
with hematoxylin-eosin using standard protocols. Picrosirius red staining was visualized 
under brightfield and polarized light using a Nikon Eclipse T2000U (Nikon, 
Amstelveen, The Netherlands) and a Leica DM LS2 microscope (Leica Microsystems, 
Solms, Germany). Immunohistochemical stainings were performed to detect LOX, 
LOXL 1 to 4, -smooth muscle actin (-SMA), phospho-Smad2, hypoxia-induced 
factor 1 (HIF1), cardiac troponin I (cTNI), and the leukocyte antigen CD45. The 
following primary antibodies were used: anti-LOX (Ab31238, Abcam, Cambridge, 
Massachusetts), anti-LOXL1, anti-LOXL2, anti-LOXL3, anti-LOXL4, anti--SMA (sc-
166632, sc-66950, sc-365286, sc-66952, sc-32251, Santa Cruz Biotechnology, Dallas, 
Texas), anti-phospho Smad2 (3101, Cell signaling Technology, Beverly, 
Massachusetts), anti-HIF1 (NB100-105SS, Novus Biologicals, Littleton, Colorado), 
anti-c-TNI (ab-47003, Abcam, Cambridge, Massachusetts) anti-CD45 (550539, BD 
Pharmigen, USA). Quantification of stained sections was done by digital image analysis 
using ImageJ (National Institutes of Health, Bethesda, Maryland) and NIS-Elements 
software (Nikon). Double immunofluorescence studies with anti-LOX/-SMA 
antibodies were done with paraffin-embedded heart tissue sections following protocols 
previously described 4. Histological and immunohistochemical studies were done by 
visualizing at least ten fields of view per section, and blinded analyzed.  
Infarct size was histologically quantified from Picrosirius red-stained whole tissue 
sections by determining the percentage of area occupied by the scar with respect to the 
total area of the left ventricle; and also by measuring the midline infarct length 
compared to the whole myocardial midline as previously described 5. 
 
RNA extraction and quantitative real-time reverse-transcribed polymerase chain 
reaction 
For RNA studies, heart tissue was snap-frozen in liquid nitrogen. Total RNA was 
extracted using the RNAeasy kit (Qiagen), the cDNA was synthesized (iScript cDNA 
synthesis kit, Bio-Rad, Hercules, California) and quantitative real time reverse-
transcribed polymerase chain reaction (RT-PCR) was performed as described with off-
the-shelf Taqman probes (Applied Biosystems, Foster City, California) 1. Analysis was 
performed with the ΔΔCt method with a GAPDH probe for normalization. 
 
Collagen and collagen cross-linking analysis 
Heart tissue portions were hydrolyzed (110°C, 24 hours) in 6 M HCl and collagen 
(hydroxyproline and proline) and mature trivalent cross-links, hydroxylysylpyridinoline 
(HP) and lysylpyridinoline (LP), analyzed as described previously6. Briefly, the samples 
were dried and redissolved in 0.4 ml 0.1 M sodium borate buffer (pH 9.5) containing 10 
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μmol/L pyridoxine (internal standard for the cross-links HP and LP) and 2.4 mM 
homoarginine (internal standard for amino acids) (Sigma-Aldrich). Samples were 
diluted 20-fold with 50% (vol/vol) acetic acid (Merck, Darmstadt, Germany) for cross-
link analysis. Samples were diluted 250-fold with 0.1 M sodium borate buffer (pH 9.5) 
for amino acid analysis. Derivatization of the amino acids with o-phtaldialdehyde, 
iodoacetamide and 9-fluorenylmethyl chloroformate and reversed-phase high-
performance liquid chromatography (HPLC) of amino acids and cross-links was 
performed on a 150 mm×4.6 mm Micropak ODS-80TM column (Tosoh Biosciece) and 
a partisil 10SCX analytical column (Inacom Instruments), respectively. The amount of 
collagen is expressed as the hydroxyproline/proline (Hyp/Pro) ratio, and of the cross-
link hydroxylysylpyridinoline (HP) as mol HP per mol collagen, assuming 300 
hydroxyproline residues per triple helical collagen molecule.  
 
Culture of cardiac fibroblasts 
Cardiac fibroblasts were isolated from 8-week old mouse heart tissue using methods 
previously described 7. Cells were grown at 37°C and humidified atmosphere of 5% 
CO2. The purity of mouse cardiac fibroblasts was determined by the expression of 
vimentin. Cells were used between 3rd and 6th passages. -SMA expression was 
routinely checked by immunoblotting in order to monitor constitutive myofibroblast 
differentiation. Mouse cardiac fibroblasts were treated for time periods ranging from 8 
to 48 hours with TGF-1 at 5 ng/ml under normoxic or hypoxic conditions (1% O2 
tension, Hypoxystation H35, Don Whitley, Shipley, England). At the end of the 
experimental period, total RNA or protein were extracted and analyzed following 
protocols previously described 4 
 
Statistical Analysis 
Data are presented as mean ± SE. In echocardiographic data, the same mice were 
analysed 3 and 28 days post-infarction, with non-infarcted animals representing a 
different group of mice. To test for statistical significance, data were analysed by two-
way ANOVA followed by Bonferroni post-test for multiple comparisons. In addition, a 
two-way ANOVA with repeated measures followed by Bonferroni post-test was applied 
to compare mice at 3 vs. 28 days post-infarction. Group differences in quantitative RT-
PCR, and histological/immunohistochemical/biochemical quantifications were analysed 
by one-way ANOVA followed by Bonferroni's post-test. Differences in infarct size by 
echocardiography were analyzed by unpaired t-test. Statistics was performed with 
GraphPad Prism 5.0 (La Jolla, California), and differences were considered statistically 
significant at P< 0.05. 
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Suppl. Figure 1. Collagen accumulation in a myocardial infarction mouse model. Time course of collagen accumulation
in mice subjected to myocardial infarction as visualized by Picrosirius red staining under brightfield. (A) Representative
micrographs, (B) the percentage of area occupied by staining (scar area), and (C) the left ventricle wall thickness (in mm) at
the site of infarct are shown (mean ± standard error; one-way ANOVA followed by Bonferroni’s post test, n = 5, *P<0.05
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Suppl. Figure 2. Analysis of LOX expression in cardiomyocytes and leukocytes upon MI.
Consecutive heart tissue sections from control and MI mice (7 days post-infarction) were analyzed
by immunohistochemistry for the expression of the canonical LOX, of the cardiomyocyte-specific
marker cardiac troponin I (cTNI), and of the leukocyte marker CD45. Overall LOX staining
associated to cTNI-positive cardiomyocytes increased upon injury, indicating that these cells
contribute to LOX expression in myocardial infarction, though to a lesser extent than myofibroblasts


































































Suppl. Figure 3. Induction of myofibroblast phenotype by TGF-b in cultured cardiac fibroblasts. A) The effect of TGF-b (5
ng/ml), hypoxia (1% O2), or both stimuli together (48 hours of incubation), on the expression of a-SMA mRNA was determined
by quantitative RT-PCR (fold change as mean ± standard error; one-way ANOVA followed by Bonferroni’s post test, n=5,
*P<0.05 versus unstimulated). Time course of a-SMA protein induction by TGF-b analyzed by immunoblotting. B)
Representative gels assayed with a-SMA and b-actin (loading control) antibodies. C) a-SMA protein intensities normalized to































































































































































Suppl. Figure 4. Expression levels of LOX isoforms (Lox and Loxl1-4), matrix metalloproteases (Mmp2 and Mmp9), and its
inhibitor Timp4 in the infarct regions of control and MI mice treated with or without BAPN. mRNA expression was determined
by real time quantitative RT-PCR (fold change as mean ± standard error; one-way ANOVA followed by Bonferroni’s post test, n=5,
*P<0.05 versus no infarction, **P<0.01 versus no infarction).
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SUPPLEMENTAL TABLE 1 
 
No MI No MI+BAPN MI MI+BAPN d0 MI+BAPN d8 
5.71±0.18 6.07±0.23 6.51±0.19* 5.81±0.28† 5.92±0.32† 
 
Supplemental Table 1. Administration of BAPN after infarction reduces the 
hypertrophic response of the heart upon MI. Control and infarcted mice received 
vehicle or BAPN starting at day 0 (d0) or 8 days after surgery (d8), and were sacrificed 
28 days post-infarction. The hypertrophic index was calculated as the heart weight/body 
weight ratio (*p<0.05 infarcted vs no MI, †p<0.05 BAPN vs Control, 2-way ANOVA 
plus Bonferroni post-test.). 
 
 
